Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93861Research ArticleEffektivnost' pantoprazola (Nol'pazy) pri odnokratnom utrennem prieme 40 mg u bol'nykh gastroezofageal'noy reflyuksnoy bolezn'yu: issledovanie PAN-STARLazebnikL. B-BordinD. S-AbdulkhakovR. A-AbdulkhakovS. R-ZakharovaN. V-IvanikovI. O-NikolaevaN. N-YanovaO. B-TikhonovS. V-15082013158242928122021Copyright © 2013, Consilium Medicum2013[Vakil N, van Zanden S.V, Kahrilas P et al. The Monreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol 2006; 101:1900–20.][Лазебник Л.Б., Машарова А.А., Бордин Д.С.и др. Результаты Многоцентрового исследования «Эпидемиология Гастроэзофагеальной РЕфлюксной болезни в России» («МЭГРЕ»). Терапевт. арх. 2011; 1: 45–50.][Dent J, El-Serag H.B, Wallander M.A et al. Epidemiology of gastro - oesophageal reflux disease: A systematic review. Gut 2005; 54: 710–7.][Van Pinxteren B, Numan M.E, Bonis P.A et al. Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro - oesophageal reflux disease - like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004; 4: CD002095.][Thomson A.B. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2000; 2 (6): 482–93.][Blume H, Donath F, Warnke A, Schug B.S. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29 (9): 769–84.][Стандарты диагностикии лечения кислотозависимыхи ассоциированныхс Helicobacter pylori заболеваний (четвертое Московское соглашение). Экспериментальнаяи клиническая гастроэнтерология. 2010; 5: 113–8.][Бордин Д.С. Как выбрать ингибитор протонной помпы больному ГЭРБ? Эксперим.и клин. гастроэнтерология. 2010; 2: 53–8.][Pace F, Tonini M, Pallotta S et al. Systematic review: maintenance treatment of gastro - oesophageal reflux disease with proton pump inhibitors taken 'on - demand'. Aliment Pharmacol Ther 2007; 26: 195–204.][Graham D.Y, Opekun A.R, Yamaoka Y et al. Early events in proton pump inhibitor - associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 2003; 17 (2): 193–200.][Исаков В.А. Ингибиторы протонного насоса: их свойстваи применениев гастроэнтерологии. М.: ИКЦ «Академкнига», 2001: с. 14.][Захарова Н.В. Лансопразол: особенности клинической фармакологии ИПП. Клиническая гастроэнтерологияи гепатология. Рус. издание. 2008; 3: 205–11.][Ткач С.М. Сходстваи различия ингибиторов протонной помпы: какой препарат считать оптимальным? Сучасна гастроентерологiя 2003; 2: 89–93.][Bardou M, Martin J. Pantoprazole: from drug metabolism to clinical relevance. Expert Opin Drug Metab Toxicol 2008; 4: 471–83.][Besancon M, Simon A, Sachs G, Shin J.M. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272 (36): 22438–46.][Spicer Z, Clarke L.L, Gawenis L.R, Shull G.E. Colonic H(+)-K(+)-ATPase in K(+) conservation and electrogenic Na(+) absorption during Na(+) restriction. Am J Physiol Gastrointest Liver Physiol 2001; 281 (6): 1369–77.][Marteau C, Sastre B, Iconomidis N et al. pH regulation in human gallbladder bile: study in patients with and without gallstones. Hepatology 1990; 11 (6): 997–1002.][Wang W.H, Giebisch G. Regulation of potassium (K) handling in the renal collecting duct. Pflugers Arch 2009; 458 (1): 157–68.][Bonanno J.A. K (+)-H+ exchange,a fundamental cell acidifier in corneal epithelium. Am J Physiol 1991; 260: 618–25.][Mc Donough A.A, Youn J.H. Role of muscle in regulating extracellular [K+]. Semin Nephrol 2005; 25 (5): 335–42.][Suzuki M, Suzuki H, Hibi T. Proton pump inhibitors and gastritis. J Clin Biochem Nutr 2008; 42 (2): 71–5.][Zedtwitz-Liebenstein K, Wenisch C, Patruta S et al. Omeprazole treatment diminishes intra– and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30: 1118–22.][Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K+-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53: 21–5.][Лапина Т.Л. Безопасность ингибиторов протонной помпы. Клин. перспективы гастроэнтерологии, гепатологии. 2009; 4: 29–35.][Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cell activity. Gen Pharmacol 1995; 26: 1413–8.][Sarkar M, Hennessy S, Yang Y.X. Proton - pump inhibitor use and the risk for community - acquired pneumonia. Ann Intern Med 2008; 149 (6): 391–8.][Blume H, Donath F, Warnke A, Schug B.S. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29 (9): 769–84.]